

GST NO : 24AAACN6841KIZD CIN : L2

17th May, 2022

996J1992PLC018210

To The General Manager-Listing Corporate Relationship Department BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai

Ref.: Script Code: 543207

Dear Sir,

Sub.: Outcome of Board Meeting

With reference to above subject and in compliance with the SEBI (LODR) 2015, we hereby submit the outcome of the Meeting of the Board of Directors held on today i.e. 17th May, 2022 at 11:00 a.m. and concluded on 12:10 p.m.:-

- 1. Considered, approved and adopted the Audited Financial Results for the Quarter and Year ended on 31st March, 2022 along with the Auditor's Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
- 2. Acceptance of resignation of CS Prakhar Dubey (ACS-65011) from the post of Company Secretary and Compliance Officer of the company.
- 3. Reviewed the Business of the Company.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully, Natural Biocon (India) Ltd



17th May, 2022

To The General Manager-Listing Corporate Relationship Department BSE Limited, Ground Floor, P.J. Towers, Dalal Street, Mumbai

Ref.: Script Code: 543207

Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to above, we hereby state that the statutory Auditor of the Company Mr. Sanket Shah have issued an Audit Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the quarter and year ended 31st March, 2022 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking You

Yours faithfully, Natural Biocon (India) Ltd

| | Financial res | ults by compar | ny | | |
|----------------------------------------------|-------------------|----------------|-----------------------------------------|--------------|--------------|
| ART I | | | | | (Rs. in Lakh |
| Statement of Standalone | Audited Results f | or the Quarter | and Year Ended | 31/03/2022 | |
| Particulars | Ouarter Ended | | | Year Ended | |
| | (31/03/2022) | (31/12/2021) | (31/03/2021) | (31/03/2022) | (31/03/2021 |
| | (01/00/2022) | (01/12/2021) | (01/00/2021) | (01/00/2022) | (01/00/2023 |
| (Refer Notes Below) | (Audited) | (Unaudited) | (Audited) | (Audited) | (Audited) |
| | (Refer Note 4) | (enuunieu) | (Refer Note 4) | (11441104) | (Financen) |
| | (itelei itote i) | | (Itelef Fible I) | | |
| 1 Revenue from Operation | 24.02 | 5.25 | 1.55 | 48.18 | 13.19 |
| | 21.02 | 5.25 | | 10.10 | |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Revenue (I + II) | 24.02 | 5.25 | 1.55 | 48.18 | 13.19 |
| 2 Expenses | 21.02 | 5.25 | 1.55 | 10.10 | 15.17 |
| (a) Cost of materials consumed | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (b) Purchase of stock-in-trade | 25.59 | 0.00 | 5.72 | 28.75 | 0.00 |
| © Changes in inventories of finished goods, | 0.00 | 2.25 | 0.00 | 0.00 | 8.87 |
| work-in-progress and stock-in-trade | 0.00 | 2.23 | 0.00 | 0.00 | 0.07 |
| (d) Employee benefits expense | 0.09 | 0.38 | 0.45 | 2.54 | 1.44 |
| (e) Finance Cost | 0.09 | 0.38 | 0.04 | 0.09 | 0.06 |
| (f) Depreciation and amortisation expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (g) Other expenses | 2.01 | 1.24 | 2.38 | 8.02 | 2.45 |
| (g) other expenses | 2.01 | 1.24 | 2.38 | 0.02 | 2.43 |
| Total expenses | 27.75 | 3.87 | 8.59 | 39.40 | 12.82 |
| 3 Profit / (Loss)before exceptional and | (3.73) | 1.38 | (7.04) | 8.79 | 0.37 |
| extraordinary items and tax (III - IV) | (3.73) | 1.56 | (7.04) | 0.79 | 0.57 |
| extraordinary items and tax (iii iiv) | | | | | |
| 4 Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 5 Profit / (Loss) before extraordinary items | (3.73) | 1.38 | (7.04) | 8.79 | 0.37 |
| and tax (V - VI) | (5.75) | 1.50 | (7.01) | 0.77 | 0.57 |
| | | | | | |
| 6 Tax expense - Provision for taxation | | | | | |
| Current Tax - Provision for taxation | 0.57 | 0.00 | 0.09 | 2.20 | 0.09 |
| Deferred Tax | 0107 | 0.00 | 0.07 | 2120 | 0.07 |
| 7 Net Profit / (Loss) for the period | (4.30) | 1.38 | (7.13) | 6.59 | 0.28 |
| · · · · · · · · · · · · · · · · · · · | (| | (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | , | |
| 8 Other Comprehensive Income/(Loss) (net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| of tax) | 0100 | 0.00 | 0.00 | 0100 | 0.00 |
| , , | | | | | |
| 9 Total Comprehensive Income/(Loss) for | (4.30) | 1.38 | (7.13) | 6.59 | 0.28 |
| the period | , í | | , , | | |
| - | 1 | | | | |
| 10 Paid up Equity Share Capital (Face value | 1137.28 | 1137.28 | 1137.28 | 1137.28 | 1137.28 |
| of Rs. 10/- each) | | | | | |
| | | | | | |
| 11 Earnings per equity share: | | | | | |
| (1) Basic | (0.00) | 0.00 | (0.01) | 0.01 | 0.00 |
| (2) Diluted | (0.00) | 0.00 | (0.01) | 0.01 | 0.00 |

Notes:

 The Audited Financial Results for the Quarter and Year ended 31st March, 2022, have been reviewed and recommended by the Audit Committee and approved and taken on record by the Board of Directors at their respective meetings held on 17th May, 2022. The Statutory Auditors of the Company have carried out an audit for the year ended 31st March, 2022 and the Statutory Auditors have expressed an unmodified audit opinion thereon.

Natural Biocon (India) Limited

- 2 The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- 3 The Audited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 4 The figures of the quarter ended 31st March, 2022 are the balancing figures between Audited Figures in respect of the Full Financial year and the published year to date figures up to third quarter of the relevant financial year.
- 5 The Company is presently dealing in only one segment.
- 6 Figures relating to the previous year / period have been regrouped / rearranged, wherever necessary, to make them comparable with those of the current year / period.
- 7 This communication is in compliance with the SEBI (Listing Obligations & Requirement) Regulations, 2015

Date: 17.05.2022 Place: Ahmedabad By Order of the Board of Directors For Natural Biocon (India) Limited

| | | ` | |
|----------------------------------------|-----------------------------------------------------|-----------------------|--|
| Particulars | As at 31st March 2022 | As at 31st March 2021 | |
| | Audited | Audited | |
| <u>A) Assets</u> | | | |
| Non Current Assets | | | |
| Property Plant and Equipement | 0.69 | - | |
| Capital Work In Progress | 328.99 | 328. | |
| Other Intengible Assets | - | - | |
| Intengible assets under Development | - | - | |
| Financial Assets | | | |
| i) Investment | - | | |
| ii) Loan | 806.95 | 729. | |
| iii) Other Financial Assets | - | - | |
| Deferred Tax Assets (net) | - | - | |
| Other non current Assets | - | - | |
| Total Non Current Assets | 1,136.63 | 1,058. | |
| Current Assets | | | |
| Inventories | 5.52 | 5. | |
| Financial Assets | | | |
| i) Trade Receivable | 49.24 | 51. | |
| ii) Cash and Cash Equivalents | 20.93 | 3. | |
| iii) Bank Balance other than (ii)above | | - | |
| iv) Loans and Advances | 17.40 | 117. | |
| iv) Other Financial Assets | - | - | |
| Other Current Assets | - | - | |
| Total Curent Assets | 93.10 | 178. | |
| <u>Total Assets</u> | 1,229.73 | <u>1237.</u> | |
| B) Equity and Liabilities | | | |
| Equity Share Capital | 1,137.28 | 1,137. | |
| Other Equity | 67.84 | 61. | |
| Total Equity | 1,205.12 | 1,198. | |
| Non Current Liabilities | | | |
| Financial Liabilities | | | |
| i)Borrowings | - | - | |
| Defered Tax Liabilities | | - | |
| Total Non Current Liabilities | 1,205.12 | 1,198. | |
| Current Liabilities | | | |
| Financial Liabilities | | | |
| i) Borrowings | 17.30 | 35. | |
| ii) Trade Payables | 2.25 | - | |
| iii) Other Financial Liabilities | - | - | |
| Provisions | 2.77 | 0. | |
| Other Current Liabilities | 2.29 | 3. | |
| Total Current Liabilities | 24.61 | 39. | |
| Total Equity and Liabilities | 1,229.73 | 1,237.0 | |
| ate: 17.05.2022 ace: Ahmedabad | By Order of the Board o For Natural Biocon (Indi | | |

| | RCH 31, 2022 | |
|------------------------------------------------------------------------|----------------------------------------------------------|------------------------------------------|
| Particulars | For the period ended on 31.03.2022 | For the period ended on 31.03.2021 |
| A. CASH FLOW FROM OPERATING ACTIVITIES | L | |
| Profit Before Tax | 8.79 | 0.37 |
| Adjustments for: | | |
| Depreciation | 0.00 | 0.00 |
| Preliminery Exps. Written off | 0.00 | 0.00 |
| Finance Cost | 0.00 | 0.00 |
| Operating Profit before Working Capital Changes | 8.79 | 0.37 |
| Movements in Working Capital : | | |
| Decrease / (Increase) in Inventories | 0.00 | 0.00 |
| Decrease / (Increase) in Sundry Debtors | 2.58 | 9.82 |
| Decrease / (Increase) in Loans and Advances | -77.07 | 23.84 |
| Decrease / (Increase) in Current Assets | 100.28 | 0.00 |
| (Decrease) / Increase in Trade Payables | 2.25 | 0.00 |
| (Decrease) / Increase in Short Term Provisions | 2.20 | -2.43 |
| (Decrease) / Increase in Current Liabilities | -18.21 | 0.92 |
| (Decrease) / Increase in Other Current Liabilities | -0.71 | 0.00 |
| Cash (used in) / generated from operations | 20.10 | 32.52 |
| Direct Taxes Paid (net of refunds) | 2.20 | 0.09 |
| Net cash (used in) / generated from operating activities (A) | 17.90 | 32.43 |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | |
| | 0.00 | 0.00 |
| (Purchase) of Fixed Assets | -0.69 | 0.00 |
| Sale / Disposal of Fixed Assets | 0.00 | 0.00 |
| Profit on sale of Investment / Assets | 0.00 | 0.00 |
| Net cash (used in) / generated from investing activities (B) | -0.69 | 0.00 |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | |
| (Repayment) / Proceeds From Long Term Borrowings | 0.00 | -32.18 |
| (Repayment) / Proceeds From Short Term Borrowings | 0.00 | 0.00 |
| Repayment / (Proceeds) From Long Term Loans & Advances | 0.00 | 0.00 |
| Proceeds from Issue of Shares | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 |
| Dividend | 0.00 | 0.00 |
| Dividend Distribution Tax | 0.00 | 0.00 |
| Net cash (used in) / generated from financing activities (C) | - | -32.18 |
| D.NET INCREASE IN CASH AND CASH EQUIVALENTS (D)=(A+{ | 17.21 | 0.25 |
| Cash and cash equivalents at the beginning of the year | 3.72 | 3.47 |
| Cash and cash equivalents at the end of the year | 20.93 | 3.72 |
| Components of each and each equivalents | | |
| Components of cash and cash equivalents | 00.40 | 0.40 |
| Cash and cheques on hand | 20.49 | 2.42 |
| With Scheduled Banks | • • • • | |
| | 0.44 | 1.30 |
| - in Current Account - in Term Deposit Accounts | | 3.72 |
| - in Current Account - in Term Deposit Accounts | 20.93 | 0.72 |
| - in Term Deposit Accounts Date: 17.05.2022 | 20.93 By Order of the Bo For Natural Biocor | oard of Directors |
| - in Term Deposit Accounts Date: 17.05.2022 | By Order of the Bo | oard of Directors |
| - in Term Deposit Accounts Date: 17.05.2022 I Place: Ahmedabad I | By Order of the Bo For Natural Biocor | oard of Directors |
| - in Term Deposit Accounts Date: 17.05.2022 I Place: Ahmedabad I | By Order of the Bo For Natural Biocor Manish Patel | oard of Directors |
| - in Term Deposit Accounts Date: 17.05.2022 Place: Ahmedabad | By Order of the Bo For Natural Biocor | oard of Directors |



Independent Auditor's Report on Quarterly Financial Results and year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

To, The Board of Directors, Natural Biocon (India) Ltd

Report on audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Natural Biocon (India) Ltd (the company) for the year ended 31st March, 2022, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. Are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit/loss and other comprehensive income and other financial information for the period from 01st April, 2021 to 31st March, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited interim condensed



financial statement for the year ended March 31, 2022. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

SANKET SHAH CHARTERED ACCOUNTANT MEM. NO. 150873 UDIN No. 22150873AJCBJK2485



Date: 17-05-2022 Place: Ahmedabad